NASDAQ: AURA - Aura Biosciences, Inc.

Yield per half year: -46.83%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Aura Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

more details
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-10-29
ISIN US05153U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.aurabiosciences.com
Цена ао 5.99
Change price per day: 0% (5.45)
Change price per week: +4.21% (5.23)
Change price per month: -25.85% (7.35)
Change price per 3 month: -27.91% (7.56)
Change price per half year: -46.83% (10.25)
Change price per year: -24.93% (7.26)
Change price per 3 year: -68.13% (17.1)
Change price per year to date: -32.8% (8.11)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.58 8
P/E 0 0
EV/EBITDA -4 0
Total: 3.25

Efficiency

Title Value Grade
ROA, % -29.96 0
ROE, % -33.83 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2337 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 254.64 10
Yield EPS, % 10.83 2
Total: 6.4
More

Institutions Volume Share, %
Matrix Capital Management 6922870 13.98
Eventide Asset Management LLC 5802682 11.72
Adage Capital Partners GP L.L.C. 4225000 8.53
Citadel Advisors Llc 3631294 7.34
Medicxi Ventures Management (Jersey) Ltd 3039892 6.14
Nantahala Capital Management, LLC 2643720 5.34
Blackrock Inc. 2098745 4.24
Vanguard Group Inc 1730431 3.5
Decheng Capital Management III (Cayman), LLC 1163123 2.35
Goldman Sachs Group Inc 1037299 2.1



Head Job title Payment Year of birth
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k 1974 (51 year)
Ms. Julie B. Feder Chief Financial Officer 604.2k 1971 (54 years)
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer N/A 1961 (64 years)
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations N/A
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology N/A
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality N/A
Mr. Conor Kilroy General Counsel & Secretary N/A 1982 (43 years)
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development N/A 1965 (60 years)

Address: United States, Boston. MA, 80 Guest Street - open in Google maps, open in Yandex maps
Website: https://www.aurabiosciences.com